Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 391 participants.

Also called NCT06221371

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 391 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06221371
Other papers using this trial's data
  • Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial JAMA, 2026-06-02 DOI, PubMed 42099212, PMC13156799 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06221371. Randomized; single masking; primary purpose treatment. Start 2024-01-25 (actual); primary completion 2025-10-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion
Acronym
TNK-PLUS
Condition
Ischemic Stroke, Acute
Condition
Thrombolysis
Condition
Endovascular Treatment
Intervention (Drug)
Tenecteplase
Intervention (Device)
direct EVT
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Linyi People's Hospital (class: other)

Record details

Record id
cardio:ct-nct06221371
Content hash
22ad962136ece4c59643075fc9070317a9ca7c692ecf846c4df35e3a30621ff0